These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 9700986

  • 1. Antiarrhythmic effects of a novel class III drug, KCB-328, on canine ventricular arrhythmia models.
    Xue Y, Tanabe S, Nabuchi Y, Hashimoto K.
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):239-47. PubMed ID: 9700986
    [Abstract] [Full Text] [Related]

  • 2. Effects of dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs.
    Chen J, Xue Y, Eto K, Ni C, Hashimoto K.
    J Cardiovasc Pharmacol; 1996 Oct; 28(4):576-84. PubMed ID: 8891885
    [Abstract] [Full Text] [Related]

  • 3. MS-551 and KCB-328, two class III drugs aggravated adrenaline-induced arrhythmias.
    Xue Y, Yamada C, Aye NN, Hashimoto K.
    Br J Pharmacol; 1998 Aug; 124(8):1712-8. PubMed ID: 9756388
    [Abstract] [Full Text] [Related]

  • 4. Electrophysiologic and antiarrhythmic effects of the new class III antiarrhythmic drug KCB-328 in experimental canine atrial flutter.
    Rahme MM, Ungab GA, Wadhwa M, Al-Kandari F, Yao B, Gupta A, Lee K, Kim HY, Feld GK.
    J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):297-306. PubMed ID: 11584336
    [Abstract] [Full Text] [Related]

  • 5. Effects of the new class III antiarrhythmic drug MS-551 and d-sotalol on canine coronary ligation-reperfusion ventricular arrhythmias.
    Hashimoto K, Haruno A, Hirasawa A, Awaji T, Xue Y, Wu Z.
    Jpn J Pharmacol; 1995 May; 68(1):1-9. PubMed ID: 7494370
    [Abstract] [Full Text] [Related]

  • 6. Antiarrhythmic and proarrhythmic effects of sematilide in canine ventricular arrhythmia models.
    Xue YX, Eto K, Akie Y, Hashimoto K.
    Jpn J Pharmacol; 1996 Feb; 70(2):129-38. PubMed ID: 8866750
    [Abstract] [Full Text] [Related]

  • 7. Acute antiarrhythmic effects of intravenously administered amiodarone on canine ventricular arrhythmia.
    Awaji T, Wu ZJ, Hashimoto K.
    J Cardiovasc Pharmacol; 1995 Dec; 26(6):869-78. PubMed ID: 8606522
    [Abstract] [Full Text] [Related]

  • 8. Effects of an antiarrhythmic drug A-2545 on canine ventricular arrhythmia models; comparison with mexiletine and flecainide.
    Xue YX, Arita J, Aye NN, Hashimoto K.
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Dec; 358(6):649-56. PubMed ID: 9879724
    [Abstract] [Full Text] [Related]

  • 9. Antiarrhythmic effects of an aconitine-like compound, TJN-505, on canine arrhythmia models.
    Arita J, Xue YX, Aye NN, Fukuyama K, Wakui Y, Niitsu K, Maruno M, Siying C, Hashimoto K.
    Eur J Pharmacol; 1996 Dec 30; 318(2-3):333-40. PubMed ID: 9016923
    [Abstract] [Full Text] [Related]

  • 10. Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: a comparative study using other canine arrhythmia models and the new antiarrhythmic drugs, propafenone, tocainide, and SUN 1165.
    Hashimoto K, Ishii M, Komori S, Mitsuhashi H.
    Heart Vessels; 1985 Feb 30; 1(1):29-35. PubMed ID: 2419304
    [Abstract] [Full Text] [Related]

  • 11. Antiarrhythmic effect of a new class 1 antiarrhythmic drug, AN-132, on ventricular arrhythmias in beagles.
    Hashimoto K, Watanabe K, Mitsuhashi H.
    Cardiovasc Drugs Ther; 1989 Oct 30; 3(5):683-9. PubMed ID: 2488108
    [Abstract] [Full Text] [Related]

  • 12. Effects of a new antiarrhythmic drug, SD-3212, on canine ventricular arrhythmia models.
    Hirasawa A, Haruno A, Matsuzaki T, Hashimoto K.
    Jpn Heart J; 1992 Nov 30; 33(6):851-61. PubMed ID: 1299746
    [Abstract] [Full Text] [Related]

  • 13. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
    Bril A, Gout B, Bonhomme M, Landais L, Faivre JF, Linee P, Poyser RH, Ruffolo RR.
    J Pharmacol Exp Ther; 1996 Feb 30; 276(2):637-46. PubMed ID: 8632331
    [Abstract] [Full Text] [Related]

  • 14. [Effects of a new antiarrhythmic drug, KW-3407, on canine ventricular arrhythmia models].
    Wu Z, Awaji T, Motomura S, Hashimoto K.
    Nihon Yakurigaku Zasshi; 1992 Aug 30; 100(2):117-26. PubMed ID: 1427497
    [Abstract] [Full Text] [Related]

  • 15. Antiarrhythmic properties of a prior oral loading of amiodarone in in vivo canine coronary ligation/reperfusion-induced arrhythmia model: comparison with other class III antiarrhythmic drugs.
    Nagasawa Y, Chen J, Hashimoto K.
    J Pharmacol Sci; 2005 Mar 30; 97(3):393-9. PubMed ID: 15764841
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia.
    Kamiya J, Ishii M, Katakami T.
    Jpn J Pharmacol; 1992 Feb 30; 58(2):107-15. PubMed ID: 1507517
    [Abstract] [Full Text] [Related]

  • 18. Antiarrhythmic effects of a new drug, E-0747, on canine ventricular arrhythmia models.
    Mitsuhashi H, Akiyama K, Hashimoto K, Sawa Y, Hatori Y.
    Jpn J Pharmacol; 1987 Jun 30; 44(2):155-62. PubMed ID: 3656773
    [Abstract] [Full Text] [Related]

  • 19. Arrhythmia models for drug research: classification of antiarrhythmic drugs.
    Hashimoto K.
    J Pharmacol Sci; 2007 Apr 30; 103(4):333-46. PubMed ID: 17409630
    [Abstract] [Full Text] [Related]

  • 20. Effects of KT-362, a new Na and Ca influx and Ca release inhibitor, on canine ventricular arrhythmias.
    Hashimoto K, Watanabe K, Mochizuki S, Tomiyama A.
    Jpn J Pharmacol; 1989 Dec 30; 51(4):475-82. PubMed ID: 2559225
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.